PH12018502095A1 - Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof - Google Patents

Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof

Info

Publication number
PH12018502095A1
PH12018502095A1 PH12018502095A PH12018502095A PH12018502095A1 PH 12018502095 A1 PH12018502095 A1 PH 12018502095A1 PH 12018502095 A PH12018502095 A PH 12018502095A PH 12018502095 A PH12018502095 A PH 12018502095A PH 12018502095 A1 PH12018502095 A1 PH 12018502095A1
Authority
PH
Philippines
Prior art keywords
amorphizing
amorphizing agent
agent
utilization
amorphous composition
Prior art date
Application number
PH12018502095A
Inventor
Takaaki Masuda
Kahori Fujii
Hirokazu Kobayashi
Original Assignee
Nihon Nohyaku Co Ltd
Pola Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Nohyaku Co Ltd, Pola Pharma Inc filed Critical Nihon Nohyaku Co Ltd
Publication of PH12018502095A1 publication Critical patent/PH12018502095A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

The present invention addresses the problem of providing a technique for amorphizing a compound represented by general formula (1) and/or a salt thereof. Provided is an amorphizing agent for a compound represented by general formula (1) and/or a salt thereof, said amorphizing agent comprising one or more members selected from among water-soluble polymers and acids.
PH12018502095A 2016-03-31 2018-09-28 Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof PH12018502095A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016071569 2016-03-31
PCT/JP2017/012578 WO2017170509A1 (en) 2016-03-31 2017-03-28 Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof

Publications (1)

Publication Number Publication Date
PH12018502095A1 true PH12018502095A1 (en) 2019-07-15

Family

ID=59964539

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502095A PH12018502095A1 (en) 2016-03-31 2018-09-28 Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof

Country Status (8)

Country Link
JP (1) JP7021827B2 (en)
KR (1) KR102359641B1 (en)
CN (1) CN108883190B (en)
AU (1) AU2017244688B2 (en)
MY (1) MY197992A (en)
PH (1) PH12018502095A1 (en)
SG (1) SG11201808660UA (en)
WO (1) WO2017170509A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017181387A (en) * 2016-03-31 2017-10-05 株式会社ポーラファルマ Evaluation method of film formed by pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3959205B2 (en) 1999-08-04 2007-08-15 ポーラ化成工業株式会社 Surface-treated powder and external preparation for skin containing the same
EP2389938B1 (en) 2002-06-18 2013-05-22 Pola Pharma Inc. Antifungal medicinal compositions
JP2006312598A (en) 2005-05-09 2006-11-16 Pola Chem Ind Inc Medicinal composition
RU2419429C2 (en) * 2006-03-08 2011-05-27 Нихон Нохияку Ко.,Лтд. Pharmaceutical composition for external application
WO2007102243A1 (en) * 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
JP4999412B2 (en) 2006-09-20 2012-08-15 ポーラ化成工業株式会社 Fine particle powder and method for producing the same
CN101808638B (en) * 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
KR101409789B1 (en) * 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 Antimycotic pharmaceutical composition
CA2844827A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
JP5662495B2 (en) * 2013-02-08 2015-01-28 株式会社ポーラファルマ Pharmaceutical composition in solubilizer form
JP6503626B2 (en) * 2013-03-28 2019-04-24 大正製薬株式会社 Pharmaceutical composition
JP5587488B1 (en) * 2013-12-12 2014-09-10 株式会社ポーラファルマ Evaluation method and index substance of preparation containing luliconazole

Also Published As

Publication number Publication date
JP2017186317A (en) 2017-10-12
CN108883190A (en) 2018-11-23
WO2017170509A1 (en) 2017-10-05
AU2017244688B2 (en) 2022-11-10
CN108883190B (en) 2022-07-01
MY197992A (en) 2023-07-25
SG11201808660UA (en) 2018-11-29
JP7021827B2 (en) 2022-02-17
KR20180126058A (en) 2018-11-26
AU2017244688A1 (en) 2018-11-22
KR102359641B1 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
SG11201804121RA (en) Novel biphenyl compound or salt thereof
AU2018312326A2 (en) Heterocyclic compound and use thereof
MX2018005292A (en) Acc inhibitors and uses thereof.
MX2021010885A (en) Pyrimidinyloxy benzene derivatives as herbicides.
PH12020500673A1 (en) Compounds
MY196413A (en) Substituted Carbonucleoside Derivatives Useful as Anticancer Agents
MX2018000050A (en) Phenoxyhalogenphenylamidines and the use thereof as fungicides.
MX2019014104A (en) Novel biphenyl compound or salt thereof.
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MX2022014864A (en) Bisamide sarcomere activating compounds and uses thereof.
MX2018007418A (en) Benzamide compounds and their use as herbicides.
PE20170439A1 (en) DERIVED FROM BIS (ARIL) CATECOL AS HERBICIDES
MY192425A (en) Polymorphs
EA202090368A1 (en) LYSOPHOSPHATID ACID RECEPTOR COMPOUNDS 1 (LPAR1)
MY177933A (en) Herbicidal composition comprising quizalofop-p
MX2018001517A (en) Substituted guanidine derivative.
MX2020006370A (en) Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same.
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2018166993A3 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
PH12018502095A1 (en) Amorphizing agent, amorphous composition comprising amorphizing agent and utilization thereof
IN2014MU00626A (en)
PH12019501977A1 (en) Additive composition for ground improvement